Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective

References

• Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10(12):1911–1918.
   PubMed Web of Science ®Google Scholar
• Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19(5):624–631.
   PubMed Web of Science ®Google Scholar
• Schetelig J, Rollig C, Kayser S, et al. Validation of the ELN 2017 Classification for AML with intermediate risk cytogenetics with or without NPM1-mutations and high or low Ratio FLT3-ITDs. Blood. 2017;130:2694.
   Web of Science ®Google Scholar
• O'Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(7):926–957.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454–464.
   PubMed Web of Science ®Google Scholar
• Larson RA, Mandrekar SJ, Sanford BL, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations. Oral Abstract #145: 59th ASH Annual Meeting and Exposition, Atlanta, GA, 2017.
   Google Scholar
• Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with -ITD. Blood. 2019;133(8):840–851.
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory-mutated AML. N Engl J Med. 2019;381(18):1728–1740.
   PubMed Web of Science ®Google Scholar
• Luger SM, Sun Z, Loghavi S, et al. Phase II randomized trial of gilteritinib vs midostaurin in newly diagnosed FLT3Mutated Acute Myeloid Leukemia (AML). 2019 ASH Annual Meeting, December 7-10, 2019. Abstract 1309.
   Google Scholar
• Cortes JE, Altman A, Ritchie EK, et al. A Phase II/III multicenter open-label 3-arm study of gilteritinib plus azacitidine or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive AML patient ineligible for intensive induction chemotherapy. J Clin Onc. 2017;35(15):TPS7068.
   Google Scholar
• Levis MJ, Hamadani M, Logan BR, et al. A phase 3 trial of gilteritinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD + AML. 2019 ASH Annual Meeting, December 7–10, 2019. Protocol 1506.
   Google Scholar
• Perl AE, Daver NG, Pratz KW, et al. Venetoclax in combination with gilteritinib in patients with relapsed/refractory acute myeloid leukemia: a phase 1b study. 2019 ASH Annual Meeting, December 7–10, 2019. Abstract 3910.
   Google Scholar
• Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993–3002.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD Acute Myeloid Leukemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984–997.
   PubMed Web of Science ®Google Scholar
• NCT02668653. Quizartinib with standard of care chemotherapy and as continuation therapy in patients with newly diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First), 2016.
   Google Scholar
• Walter RB. Addition of crenolanib to standard induction and consolidation therapy improved long term outcomes in newly diagnosed FLT3-Mutant AML ≤60 Years Old. European Hematology Association, June 15 2018. Abstract PF227.
   Google Scholar
• Wang ES, Griffiths EA, Walter RB, et al. Tolerability and efficacy of crenolanib and cytarabine/anthracycline chemotherapy in older patients (aged 61 to 75) with newly diagnosed FLT3-mutated Acute Myeloid Leukemia (AML). Blood. 2019;134(Supplement_1):3829–3829.
   Google Scholar
• Stone RM, Wang ES, Goldberg AD, Et al. Crenolanib vs midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML. J Clin Onc. 2019;37(15):TPS7068.
   Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Kadia TM, et al. Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. Abstract #7008. Presented at the 2016 American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 4, 2016.
   Google Scholar
• NCT02400255. Crenolanib maintenance following allogeneic stem cell transplant in FLT3-positive Acute Myeloid Leukemia Patients, 2015.
   Google Scholar
• Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006;5(7):1854–1863.
   PubMed Web of Science ®Google Scholar
• Kim HP, Gerhard B, Harasym TO, et al. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol. 2011;39(7):741–750.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123(21):3239–3246.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Newell LF, et al. Outcomes in patients with therapy-related acute myeloid leukemia who achieved remission with CPX-351 versus 7 + 3: phase 3 exploratory analysis. 2019 ASH Annual Meeting, December 7–10, 2019.
   Google Scholar
• Goldberg AD, Talati C, Desai P, et al. TP 53 mutations predict poorer responses to CPX-351 in Acute Myeloid Leukemia. Blood. 2018;132(supplement 1):1433–1433.
   Google Scholar
• Ritchie EK, Miah SK, Lee S, et al. CPX-351 as first intensive therapy for elderly patients with AML. Blood. 2019; 134(Supplement_1):3858–3858.
   Google Scholar
• NCT04195945. CPX-351 or CLAG-M Regimen for the treatment of acute myeloid leukemia or other high-grade myeloid neoplasms in medically less-fit patients, 2019.
   Google Scholar
• NCT04269213. CPX-351 for the treatment of secondary acute myeloid leukemia in patients younger than 60 years old, 2020.
   Google Scholar
• NCT03826992. Venetoclax Combines with Vyxeos (CPX-351) for participants with relapsed or Refractory Acute Leukemia, 2018.
   Google Scholar
• NCT03904251. CPX-351 and gemtuzumab ozogamicin in treating patients with relapse Acute Myeloid Leukemia, 2019.
   Google Scholar
• NCT04231851. CPX-351 and glasdegib for newly diagnosed acute myelogenous leukemia with MDS related changes or therapy-related acute myeloid leukemia, 2020.
   Google Scholar
• NCT03825796. CPX-351 and enasidenib in treating patient with relapsed acute myeloid leukemia characterized by IDH2 mutation, 2019.
   Google Scholar
• Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–4860.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–1516.
   PubMed Web of Science ®Google Scholar
• Lambert J, Pautas C, Terré C, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104(1):113–119.
   PubMed Web of Science ®Google Scholar
• Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–996.
   PubMed Web of Science ®Google Scholar
• Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21(1):66–71.
   PubMed Web of Science ®Google Scholar
• Walter RB, Gooley TA, van der Velden VHJ, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007;109(10):4168–4170.
   PubMed Web of Science ®Google Scholar
• Olombel G, Guerin E, Guy J, et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood. 2016;127(17):2157–2160.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Bernstein ID. Gemtuzumab ozogamicin for acute myeloid leukemia. Blood. 2017;130(22):2373–2376.
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773.
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24(5):1094–1096.
   PubMed Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058–1066.
   PubMed Web of Science ®Google Scholar
• Patel KP, Ravandi F, Me D, et al. Acute myeloid leukemia with IDH1 or IDH 2 mutations: frequency and clinicopathologic features. Am J Clin Pathol. 2011;135(1):35–45.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, De Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398.
   PubMed Web of Science ®Google Scholar
• Fernandez PM. AGILE: a phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation. 2019 ASH Annual Meeting, December 7–10, 2019. Abstract 2593.
   Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731.
   PubMed Web of Science ®Google Scholar
• Norsworthy KJ, Mulkey F, Ward AF, et al. Incidence of differentiation syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for treatment of patients with Relapsed or Refractory (R/R) isocitrate dehydrogenase (idh)1- or idh2-mutated acute myeloid leukemia (aml): a systematic analysis by the U.S. food and drug administration (FDA). Blood. 2018;132(Supplement 1):288–288.
   Google Scholar
• Fathi AT, DiNardo CD, Kline I, et al. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study. JAMA Oncol. 2018;4(8):1106–1110.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463–471.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions. 2018 ASH annual Meeting. Dec. 3, 2018. Abstract 560.
   Google Scholar
• Dinardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677.
   PubMed Web of Science ®Google Scholar
• Wei AH, Strickland SA, Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277–1284.
   PubMed Web of Science ®Google Scholar
• NCT03069352. A study of venetoclax in combination with low dose cytarabine versus low dose cytarabine alone in treatment naive patients with acute myeloid leukemia who are ineligible for intensive chemotherapy, 2017.
   Google Scholar
• NCT02993523. A study of venetoclax in combination with azacitidine versus azacitidine in treatment naïve subjects with acute myeloid leukemia who are ineligable for standard induction therapy, 2016.
   Google Scholar
• Goldberg AD, Horvat TZ, Meier H, et al. Venetoclax combined with either hypomethylating agent or low dose cytarabine shows activity in relapsed and refractory myeloid malignancies. 2018 ASH Annual Meeting, December 7, 2018. Abstract 616.
   Google Scholar
• Aldoss I, Yang D, Aribi A, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018;103(9):e404–e407.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–407.
   PubMed Web of Science ®Google Scholar
• NCT03471260. Phase Ib/II investigator sponsored study of the IDH1-mutant inhibitor ivosidenib (AG120) With the BCL2 inhibitor venetoclax in IDH1-mutated hematologic malignancies, 2020.
   Google Scholar
• DiNardo CD, Takahashi K, Kadia T, et al. A phase 1b/2 clinical study of targeted IDH1 inhibition with ivosidenib, in combination with the BCL2 inhibitor venetoclax, for IDH1-mutated myeloid malignancies. In: 24th Annual Congress of the European Hematology Association, Amsterdam, Holland, 13–16 June 2019. Abstract PF297: 97–97.
   Google Scholar
• Cortes JE, Douglas Smith B, Wang ES, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results. Am J Hematol. 2018;93(11):1301–1310.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Dombret H, Merchant A, et al. Glasdegib plus intensive/non-intensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncol. 2019;15(31):3531–3545.
   PubMed Web of Science ®Google Scholar
• Wei AH, Döhner H, Pocock C, et al. The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-bind, placebo-controlled study of CC-486 (Oral Formulation of Azacitidine) in patients with Acute Myeloid Leukemia (AML) in First Remission. 2019 ASH Annual Meeting, December 7, 2019. Abstract LBA3.
   Google Scholar
• Sallman DA, Malki MA, Asch AS, et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacytidine in MDS and AML patients: phase Ib results. J Clin Oncol. 2020;38(15_suppl):7507–7507.
   Web of Science ®Google Scholar
• Byukov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by low-molecular-weight compound. Nat. Med. 2002;8:282–288.
   PubMed Web of Science ®Google Scholar
• Sallman DA, DeZern AE, Steensma DP, et al. Phase 1b/2 combination study of APR-246 and azacitidine in patients with TP53 mutant myelodysplastic syndromes and acute myeloid leukemia. Blood. 2018;132(Supplement 1):3091–3091.
   Google Scholar